Healthcare provider profile · identity verified

Todd Mitchell Antin, MD

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · DECATUR, GA · NPI 1598714073

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Todd Mitchell Antin, MD received $164,814.66 in general payments during 2025 across 217 reported records.

Teva Pharmaceuticals USA, Inc. accounted for 57.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 21 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Trintellix.

Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ingrezza by this doctor in 2024.

Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trintellix by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$164,814.66

217 reported records · 15 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$93,872.11	57.0%	72	2025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$48,670.48	29.5%	74	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$14,426.56	8.8%	27	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$7,112.28	4.3%	12	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$155.93	0.1%	7	2025
Janssen Pharmaceuticals, Inc	Unresolved — no canonical attribution shown	$127.87	0.1%	5	2025
Neurocrine BioSciences, Inc.	Unresolved — no canonical attribution shown	$120.70	0.1%	4	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$79.19	0.1%	4	2025
ACADIA Pharmaceuticals Inc	Unresolved — no canonical attribution shown	$64.04	0.0%	3	2025
Collegium Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$61.31	0.0%	3	2025
Takeda Pharmaceuticals U.S.A., Inc.	Unresolved — no canonical attribution shown	$44.52	0.0%	2	2025
Supernus Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$26.78	0.0%	1	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$18.39	0.0%	1	2025
Tris Pharma Inc	Unresolved — no canonical attribution shown	$18.11	0.0%	1	2025
Bausch Health US, LLC	Unresolved — no canonical attribution shown	$16.39	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$136,906.00	41
Travel and Lodging	$11,797.63	53
Consulting Fee	$11,797.50	8
Food and Beverage	$4,313.53	115

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$56,447.73	46	2025
Source payment records 2025-01-23 · Teva Pharmaceuticals USA, Inc. · $2,601.00 · Open Payments source 2025-01-27 · Teva Pharmaceuticals USA, Inc. · $1,301.00 · Open Payments source 2025-02-19 · Teva Pharmaceuticals USA, Inc. · $2,601.00 · Open Payments source 2025-03-06 · Teva Pharmaceuticals USA, Inc. · $168.00 · Open Payments source 2025-03-06 · Teva Pharmaceuticals USA, Inc. · $4,877.00 · Open Payments source 2025-03-06 · Teva Pharmaceuticals USA, Inc. · $9.93 · Open Payments source 2025-03-06 · Teva Pharmaceuticals USA, Inc. · $175.00 · Open Payments source 2025-03-06 · Teva Pharmaceuticals USA, Inc. · $2,601.00 · Open Payments source 2025-03-06 · Teva Pharmaceuticals USA, Inc. · $2.07 · Open Payments source 2025-03-06 · Teva Pharmaceuticals USA, Inc. · $17.56 · Open Payments source 2025-03-06 · Teva Pharmaceuticals USA, Inc. · $120.79 · Open Payments source 2025-03-13 · Teva Pharmaceuticals USA, Inc. · $1,301.00 · Open Payments source 2025-04-02 · Teva Pharmaceuticals USA, Inc. · $16.00 · Open Payments source 2025-04-02 · Teva Pharmaceuticals USA, Inc. · $39.20 · Open Payments source 2025-04-02 · Teva Pharmaceuticals USA, Inc. · $3,251.00 · Open Payments source 2025-04-15 · Teva Pharmaceuticals USA, Inc. · $61.60 · Open Payments source 2025-04-15 · Teva Pharmaceuticals USA, Inc. · $3,250.00 · Open Payments source 2025-05-08 · Teva Pharmaceuticals USA, Inc. · $47.22 · Open Payments source 2025-05-14 · Teva Pharmaceuticals USA, Inc. · $1,500.42 · Open Payments source 2025-05-14 · Teva Pharmaceuticals USA, Inc. · $4,876.00 · Open Payments source 2025-08-21 · Teva Pharmaceuticals USA, Inc. · $832.26 · Open Payments source 2025-08-21 · Teva Pharmaceuticals USA, Inc. · $4,876.00 · Open Payments source 2025-08-21 · Teva Pharmaceuticals USA, Inc. · $17.31 · Open Payments source 2025-08-22 · Teva Pharmaceuticals USA, Inc. · $19.00 · Open Payments source 2025-08-28 · Teva Pharmaceuticals USA, Inc. · $10.00 · Open Payments source 2025-08-28 · Teva Pharmaceuticals USA, Inc. · $39.20 · Open Payments source 2025-08-28 · Teva Pharmaceuticals USA, Inc. · $3,250.00 · Open Payments source 2025-08-28 · Teva Pharmaceuticals USA, Inc. · $1.57 · Open Payments source 2025-08-29 · Teva Pharmaceuticals USA, Inc. · $705.00 · Open Payments source 2025-09-09 · Teva Pharmaceuticals USA, Inc. · $1,006.34 · Open Payments source 2025-09-09 · Teva Pharmaceuticals USA, Inc. · $4,226.00 · Open Payments source 2025-09-09 · Teva Pharmaceuticals USA, Inc. · $124.03 · Open Payments source 2025-09-18 · Teva Pharmaceuticals USA, Inc. · $7.58 · Open Payments source 2025-09-18 · Teva Pharmaceuticals USA, Inc. · $194.60 · Open Payments source 2025-09-18 · Teva Pharmaceuticals USA, Inc. · $4,876.00 · Open Payments source 2025-09-18 · Teva Pharmaceuticals USA, Inc. · $26.48 · Open Payments source 2025-09-25 · Teva Pharmaceuticals USA, Inc. · $1,101.80 · Open Payments source 2025-09-25 · Teva Pharmaceuticals USA, Inc. · $4,876.00 · Open Payments source 2025-09-25 · Teva Pharmaceuticals USA, Inc. · $110.77 · Open Payments source 2025-09-30 · Teva Pharmaceuticals USA, Inc. · $8.21 · Open Payments source 2025-09-30 · Teva Pharmaceuticals USA, Inc. · $10.92 · Open Payments source 2025-10-20 · Teva Pharmaceuticals USA, Inc. · $4.56 · Open Payments source 2025-10-20 · Teva Pharmaceuticals USA, Inc. · $6.53 · Open Payments source 2025-10-21 · Teva Pharmaceuticals USA, Inc. · $0.21 · Open Payments source 2025-10-21 · Teva Pharmaceuticals USA, Inc. · $0.57 · Open Payments source 2025-12-08 · Teva Pharmaceuticals USA, Inc. · $1,300.00 · Open Payments source
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$48,670.48	74	2025
Source payment records 2025-04-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2.54 · Open Payments source 2025-04-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5.35 · Open Payments source 2025-04-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.77 · Open Payments source 2025-05-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.53 · Open Payments source 2025-06-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,497.50 · Open Payments source 2025-06-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $28.88 · Open Payments source 2025-06-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-07-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-07-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $91.70 · Open Payments source 2025-07-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.04 · Open Payments source 2025-07-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $95.90 · Open Payments source 2025-07-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,885.00 · Open Payments source 2025-07-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $122.73 · Open Payments source 2025-08-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.50 · Open Payments source 2025-08-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.00 · Open Payments source 2025-08-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-08-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.23 · Open Payments source 2025-08-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,885.00 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $87.50 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3.28 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.53 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $92.40 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $138.53 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $275.45 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $44.30 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $46.64 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $52.94 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $526.97 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.43 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $68.75 · Open Payments source 2025-10-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.31 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $309.75 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $118.80 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.75 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.40 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $50.40 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $60.00 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,034.95 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $96.81 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.19 · Open Payments source 2025-11-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $112.00 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.40 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.99 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.79 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.55 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.00 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $7.78 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $94.50 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.00 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $96.60 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.71 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $122.50 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.81 · Open Payments source 2025-12-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $136.50 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $107.95 · Open Payments source 2025-12-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.73 · Open Payments source 2025-12-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.05 · Open Payments source 2025-12-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.10 · Open Payments source 2025-12-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.47 · Open Payments source 2025-12-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.22 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,885.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,885.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5.30 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.40 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.80 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source
UZEDY Normalized: uzedy	Drug	Teva Pharmaceuticals USA, Inc.	$37,424.38	26	2025
Source payment records 2025-02-04 · Teva Pharmaceuticals USA, Inc. · $63.00 · Open Payments source 2025-02-04 · Teva Pharmaceuticals USA, Inc. · $3,251.00 · Open Payments source 2025-02-04 · Teva Pharmaceuticals USA, Inc. · $19.07 · Open Payments source 2025-02-18 · Teva Pharmaceuticals USA, Inc. · $6.37 · Open Payments source 2025-02-18 · Teva Pharmaceuticals USA, Inc. · $77.00 · Open Payments source 2025-02-18 · Teva Pharmaceuticals USA, Inc. · $58.10 · Open Payments source 2025-02-18 · Teva Pharmaceuticals USA, Inc. · $4,227.00 · Open Payments source 2025-02-18 · Teva Pharmaceuticals USA, Inc. · $22.07 · Open Payments source 2025-02-18 · Teva Pharmaceuticals USA, Inc. · $113.18 · Open Payments source 2025-02-18 · Teva Pharmaceuticals USA, Inc. · $2,601.00 · Open Payments source 2025-02-23 · Teva Pharmaceuticals USA, Inc. · $125.83 · Open Payments source 2025-03-11 · Teva Pharmaceuticals USA, Inc. · $1,118.61 · Open Payments source 2025-03-11 · Teva Pharmaceuticals USA, Inc. · $4,877.00 · Open Payments source 2025-03-11 · Teva Pharmaceuticals USA, Inc. · $11.68 · Open Payments source 2025-04-07 · Teva Pharmaceuticals USA, Inc. · $8,893.00 · Open Payments source 2025-04-22 · Teva Pharmaceuticals USA, Inc. · $1,301.00 · Open Payments source 2025-04-28 · Teva Pharmaceuticals USA, Inc. · $42.00 · Open Payments source 2025-04-28 · Teva Pharmaceuticals USA, Inc. · $3,250.00 · Open Payments source 2025-07-31 · Teva Pharmaceuticals USA, Inc. · $31.50 · Open Payments source 2025-07-31 · Teva Pharmaceuticals USA, Inc. · $3,250.00 · Open Payments source 2025-07-31 · Teva Pharmaceuticals USA, Inc. · $100.30 · Open Payments source 2025-09-11 · Teva Pharmaceuticals USA, Inc. · $33.60 · Open Payments source 2025-09-11 · Teva Pharmaceuticals USA, Inc. · $3,250.00 · Open Payments source 2025-09-11 · Teva Pharmaceuticals USA, Inc. · $125.00 · Open Payments source 2025-10-21 · Teva Pharmaceuticals USA, Inc. · $3.07 · Open Payments source 2025-12-07 · Teva Pharmaceuticals USA, Inc. · $574.00 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$14,426.56	27	2025
Source payment records 2025-03-17 · Vanda Pharmaceuticals Inc. · $34.99 · Open Payments source 2025-03-17 · Vanda Pharmaceuticals Inc. · $2,100.00 · Open Payments source 2025-03-17 · Vanda Pharmaceuticals Inc. · $72.24 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $10.00 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $517.97 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $605.00 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $178.12 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $5,670.00 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $46.00 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $219.22 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $51.80 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $60.00 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $2.66 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $79.73 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $3.99 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $29.52 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $69.90 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $32.61 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $49.55 · Open Payments source 2025-08-20 · Vanda Pharmaceuticals Inc. · $38.61 · Open Payments source 2025-09-17 · Vanda Pharmaceuticals Inc. · $32.04 · Open Payments source 2025-09-17 · Vanda Pharmaceuticals Inc. · $2,100.00 · Open Payments source 2025-09-17 · Vanda Pharmaceuticals Inc. · $30.80 · Open Payments source 2025-09-18 · Vanda Pharmaceuticals Inc. · $89.63 · Open Payments source 2025-09-18 · Vanda Pharmaceuticals Inc. · $2,100.00 · Open Payments source 2025-09-18 · Vanda Pharmaceuticals Inc. · $194.60 · Open Payments source 2025-09-18 · Vanda Pharmaceuticals Inc. · $7.58 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$2,957.28	7	2025
Source payment records 2025-01-14 · E.R. Squibb & Sons, L.L.C. · $24.62 · Open Payments source 2025-01-29 · E.R. Squibb & Sons, L.L.C. · $62.47 · Open Payments source 2025-02-21 · E.R. Squibb & Sons, L.L.C. · $2,769.00 · Open Payments source 2025-02-21 · E.R. Squibb & Sons, L.L.C. · $20.00 · Open Payments source 2025-02-21 · E.R. Squibb & Sons, L.L.C. · $32.90 · Open Payments source 2025-04-25 · E.R. Squibb & Sons, L.L.C. · $27.06 · Open Payments source 2025-06-23 · E.R. Squibb & Sons, L.L.C. · $21.23 · Open Payments source
REXULTI Normalized: rexulti	Drug	Lundbeck LLC, Otsuka America Pharmaceutical, Inc.	$127.07	6	2025
Source payment records 2025-01-22 · Otsuka America Pharmaceutical, Inc. · $28.65 · Open Payments source 2025-03-25 · Otsuka America Pharmaceutical, Inc. · $21.73 · Open Payments source 2025-04-29 · Otsuka America Pharmaceutical, Inc. · $19.83 · Open Payments source 2025-05-20 · Lundbeck LLC · $18.39 · Open Payments source 2025-08-26 · Otsuka America Pharmaceutical, Inc. · $21.09 · Open Payments source 2025-09-17 · Otsuka America Pharmaceutical, Inc. · $17.38 · Open Payments source
INGREZZA Normalized: ingrezza	Drug	Neurocrine BioSciences, Inc.	$120.70	4	2025
Source payment records 2025-02-25 · Neurocrine BioSciences, Inc. · $27.27 · Open Payments source 2025-03-12 · Neurocrine BioSciences, Inc. · $34.44 · Open Payments source 2025-06-10 · Neurocrine BioSciences, Inc. · $30.80 · Open Payments source 2025-07-08 · Neurocrine BioSciences, Inc. · $28.19 · Open Payments source
SPRAVATO Normalized: spravato	Drug	Janssen Pharmaceuticals, Inc	$88.13	4	2025
Source payment records 2025-04-01 · Janssen Pharmaceuticals, Inc · $24.03 · Open Payments source 2025-05-06 · Janssen Pharmaceuticals, Inc · $24.98 · Open Payments source 2025-08-12 · Janssen Pharmaceuticals, Inc · $13.72 · Open Payments source 2025-09-30 · Janssen Pharmaceuticals, Inc · $25.40 · Open Payments source
NUPLAZID Normalized: nuplazid	Drug	ACADIA Pharmaceuticals Inc	$64.04	3	2025
Source payment records 2025-03-05 · ACADIA Pharmaceuticals Inc · $19.27 · Open Payments source 2025-06-04 · ACADIA Pharmaceuticals Inc · $25.84 · Open Payments source 2025-09-09 · ACADIA Pharmaceuticals Inc · $18.93 · Open Payments source
Jornay PM Normalized: jornay pm	Drug	Collegium Pharmaceutical, Inc.	$61.31	3	2025
Source payment records 2025-04-16 · Collegium Pharmaceutical, Inc. · $23.85 · Open Payments source 2025-05-21 · Collegium Pharmaceutical, Inc. · $19.50 · Open Payments source 2025-11-05 · Collegium Pharmaceutical, Inc. · $17.96 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$56.74	3	2025
Source payment records 2025-01-07 · Axsome Therapeutics, Inc. · $15.00 · Open Payments source 2025-08-05 · Axsome Therapeutics, Inc. · $21.64 · Open Payments source 2025-10-07 · Axsome Therapeutics, Inc. · $20.10 · Open Payments source
ABILIFY ASIMTUFII Normalized: abilify asimtufii	Drug	Otsuka America Pharmaceutical, Inc.	$47.25	2	2025
Source payment records 2025-02-19 · Otsuka America Pharmaceutical, Inc. · $24.04 · Open Payments source 2025-10-28 · Otsuka America Pharmaceutical, Inc. · $23.21 · Open Payments source
ABILIFY MAINTENA Normalized: abilify maintena	Drug	Otsuka America Pharmaceutical, Inc.	$47.25	2	2025
Source payment records 2025-02-19 · Otsuka America Pharmaceutical, Inc. · $24.04 · Open Payments source 2025-10-28 · Otsuka America Pharmaceutical, Inc. · $23.21 · Open Payments source
TRINTELLIX Normalized: trintellix	Drug	Takeda Pharmaceuticals U.S.A., Inc.	$44.52	2	2025
Source payment records 2025-08-20 · Takeda Pharmaceuticals U.S.A., Inc. · $25.97 · Open Payments source 2025-11-19 · Takeda Pharmaceuticals U.S.A., Inc. · $18.55 · Open Payments source
INVEGA SUSTENNA Normalized: invega sustenna	Drug	Janssen Pharmaceuticals, Inc	$39.74	1	2025
Source payment records 2025-05-13 · Janssen Pharmaceuticals, Inc · $39.74 · Open Payments source
HETLIOZ Normalized: hetlioz	Drug	Vanda Pharmaceuticals Inc.	$38.61	1	2025
Source payment records 2025-08-20 · Vanda Pharmaceuticals Inc. · $38.61 · Open Payments source
Qelbree Normalized: qelbree	Drug	Supernus Pharmaceuticals, Inc.	$26.78	1	2025
Source payment records 2025-05-27 · Supernus Pharmaceuticals, Inc. · $26.78 · Open Payments source
Sunosi Normalized: sunosi	Drug	Axsome Therapeutics, Inc.	$22.45	1	2025
Source payment records 2025-06-24 · Axsome Therapeutics, Inc. · $22.45 · Open Payments source
Dyanavel XR Normalized: dyanavel xr	Drug	Tris Pharma Inc	$18.11	1	2025
Source payment records 2025-02-13 · Tris Pharma Inc · $18.11 · Open Payments source
APLENZIN Normalized: aplenzin	Drug	Bausch Health US, LLC	$16.39	1	2025
Source payment records 2025-07-24 · Bausch Health US, LLC · $16.39 · Open Payments source
WELLBUTRIN Normalized: wellbutrin	Drug	Bausch Health US, LLC	$16.39	1	2025
Source payment records 2025-07-24 · Bausch Health US, LLC · $16.39 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
INGREZZA ingrezza	2025	Ingrezza	2024	14 Beneficiary count suppressed	exact normalized	Medicare Part D
TRINTELLIX trintellix	2025	Trintellix	2024	15 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference	2025	INGREZZA open payments reported associated product	CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729	Ingrezza · 2024 Exact normalized brand match · 1 Part D row	14	suppressed by CMS
Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference	2025	TRINTELLIX open payments reported associated product	CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266	Trintellix · 2024 Exact normalized brand match · 1 Part D row	15	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Aripiprazole	Aripiprazole	34	12
Quetiapine Fumarate	Quetiapine Fumarate	33	13
Alprazolam	Alprazolam	29	11
Clonazepam	Clonazepam	25	suppressed
Trazodone Hcl	Trazodone Hcl	24	15
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	21	suppressed
Methylphenidate Er	Methylphenidate Hcl	21	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Lamotrigine	Lamotrigine	19	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Olanzapine	Olanzapine	18	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	16	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Trintellix	Vortioxetine Hydrobromide	15	suppressed
Benztropine Mesylate	Benztropine Mesylate	14	suppressed
Ingrezza	Valbenazine Tosylate	14	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	14	suppressed
Lisdexamfetamine Dimesylate	Lisdexamfetamine Dimesylate	13	suppressed
Divalproex Sodium Er	Divalproex Sodium	12	suppressed
Haloperidol Decanoate	Haloperidol Decanoate	11	suppressed
Methylphenidate Hcl Er (Cd)	Methylphenidate Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$164,814.66 · 217 records	Teva Pharmaceuticals USA, Inc.	ABILIFY ASIMTUFII, ABILIFY MAINTENA, APLENZIN, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, Dyanavel XR, FANAPT, HETLIOZ, INGREZZA, INVEGA SUSTENNA, Jornay PM, NUPLAZID, Qelbree, REXULTI, SPRAVATO, Sunosi, TRINTELLIX, UZEDY, WELLBUTRIN	2	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Ingrezza play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Neurocrine BioSciences, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error